Get the Stockscreener App
0.7713
0.09%
-0.000701
Trinity Biotech Plc Adr stock is traded at $0.7713, with a volume of 73,384.
It is down -0.09% in the last 24 hours and down -6.62% over the past month.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
See More
Previous Close:
$0.772
Open:
$0.7715
24h Volume:
73,384
Relative Volume:
0.04
Market Cap:
$21.23M
Revenue:
$71.39M
Net Income/Loss:
$-28.60M
P/E Ratio:
-0.2062
EPS:
-3.74
Net Cash Flow:
$-12.92M
1W Performance:
+1.49%
1M Performance:
-6.62%
6M Performance:
-67.69%
1Y Performance:
-70.33%
1-Day Range:
$0.7531
$0.7894
1-Week Range:
$0.7475
$0.8178
52-Week Range:
$0.74
$3.55
Trinity Biotech Plc Adr Stock (TRIB) Company Profile
Name
Trinity Biotech Plc Adr
Sector
Industry
Phone
-
Address
-
Compare TRIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRIB
Trinity Biotech Plc Adr
|
0.7713 | 21.23M | 71.39M | -28.60M | -12.92M | -3.74 |
|
ABT
Abbott Laboratories
|
132.13 | 229.17B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.67 | 155.74B | 16.75B | 1.85B | 1.89B | 1.25 |
|
SYK
Stryker Corp
|
388.52 | 148.25B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.00 | 111.64B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.67 | 44.04B | 5.72B | 4.17B | 490.10M | 6.97 |
Trinity Biotech Plc Adr Stock (TRIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-15 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-03-15 | Initiated | Raymond James | Outperform |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jul-22-08 | Reiterated | Roth Capital | Buy |
| Mar-17-08 | Reiterated | Roth Capital | Buy |
| Dec-10-07 | Reiterated | Roth Capital | Buy |
| Oct-26-07 | Reiterated | Roth Capital | Buy |
View All
Trinity Biotech Plc Adr Stock (TRIB) Latest News
TRIBTrinity Biotech Announces Quarter 1 Financial Results - br.ADVFN.com
Trinity Biotech Announces Quarter 2 Results Revenues of US$36.3m and Operating Profit of US$2.3m - br.ADVFN.com
Trinity Biotech Announces Quarter 4 Financial Results EPS of 17.1 Cent per Share -- an Increase of 10.3% - br.ADVFN.com
Trinity Biotech Announces Quarter 3 Results; Revenues Increase to $35.6m; Operating Profit Increases 56% - br.ADVFN.com
Trinity Biotech stock hits 52-week low at $0.74 amid market challenges - Investing.com
Trinity Biotech Announces Quarter 3 Financial Results, Acquisition of Blood Bank Screening Business and FDA Approval of HIV-2... - br.ADVFN.com
Trinity Biotech Plc ADR (TRIB) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Market Highlights: Xometry Inc (XMTR) Ends on a Low Note at 36.21 - The Dwinnex
Daily Progress: SiTime Corp (SITM) Drop -20.93, Closing at 176.32 - The Dwinnex
Trinity Biotech Plc ADR (TRIB) Shares Down Despite Recent Market Volatility - The News Heater
Trinity Biotech reports leap in CGM system accuracy - Investing.com
Trinity Biotech secures US funding for HIV tests - Investing.com
Trinity Biotech faces US aid policy impact, PPP loan scrutiny - Investing.com India
Trinity Biotech announces breakthrough in CGM technology - Investing.com India
Trinity Biotech stock hits 52-week low at $0.74 amid challenges By Investing.com - Investing.com South Africa
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Hemoglobin A1c (HbA1c) Testing Market Projected to Reach $1.83 Billion by 2024, Growth Fueled by Rising Prevalence of Diabetes - GlobeNewswire Inc.
Trinity Biotech revises credit terms to boost liquidity - Investing.com India
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan - GlobeNewswire Inc.
Trinity Biotech advances HIV test manufacturing to offshore site - Investing.com
Trinity Biotech files to sell 0.65M American Depositary shares by selling shareholders - MSN
Earnings call: Trinity Biotech Q3 2024 shows steady growth, strategic moves - Investing.com
What to look for when Lowe’s (LOW) reports Q3 2024 earnings results - AlphaStreet
Trinity Biotech regains Nasdaq compliance - Investing.com India
Trinity Biotech expands into oncology with EpiCapture buyout - Investing.com
Trinity Biotech invests in rapid sepsis diagnostics firm By Investing.com - Investing.com
Trinity Biotech advances next-gen glucose monitor - Investing.com
Trinity Biotech acquires Metabolomics Diagnostics - Investing.com
TRIB underperforms with a -14.67 decrease in share price - US Post News
Balance Sheet Breakdown: Trinity Biotech Plc ADR (TRIB)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Trinity Biotech to launch CGM tech in India, seeks feedback - Investing.com India
North America Blood Testing Market Size & Outlook, 2030 - Grand View Research
Middle East & Africa Blood Testing Market Size & Outlook, 2030 - Grand View Research
Trinity Biotech Plc Adr Stock (TRIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
11.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):